a jollibee

a jollibee Robertson has 'no regrets' over GB hockey career

PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company’s Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. “This strategic transaction highlights Vincerx’s commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer. “Oqory’s anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings.” About OQY-3258 (also known as ESG401) OQY-3258 is Oqory’s anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory’s product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx’s control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx’s capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties’ ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx’s reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.com

Has there been a ‘Karen Vibe Shift’? Viral service dog confrontation sparks debateNASA’s Parker Solar Probe made history this week, successfully completing its closest-ever approach to the Sun. On Christmas Eve, the spacecraft came within an unprecedented 3.8 million miles of the Sun’s surface, an achievement previously believed to be impossible. After numerous days of communication silence, NASA confirmed on Thursday that the spacecraft was secure and functional after its intense flyby. Scientists anticipate the information Parker will transmit on New Year's Day, providing important perspectives on the probe's functioning and solar studies. NASA's Past Releases and Anticipated New Images Since its launch in 2018, the Parker Solar Probe has returned remarkable images. Its previous near-distance encounters withthe Sun has enabled it to take images of the Sun’s corona, offering remarkable perspectives of the star's outer atmosphere. Although the probe's main objective is to collect information regarding solar activity, it has also provided visually impressive images, uncovering fresh insights into the Sun's behavior and architecture. While the probe persists in its mission, NASA is anticipated to unveil additional images and data from Parker's closest flyby of the Sun. Parker Solar Probe’s Engineering Marvel: A Close Encounter Experts consider the Parker Solar Probe a remarkable engineering accomplishment in space exploration. Its specialized thermal shield allows the spacecraft to withstand harsh conditions, tolerating temperatures reaching 2,500°F as it approaches the Sun. This thermal shield guarantees that the scientific instruments, situated at the back of the probe, stay in a consistent, room-temperature setting. The shield's efficiency is vital in stopping the spacecraft from incinerating. In its earlier flybys, notably the one over Venus in November, the Parker Solar Probe harnessed the planet's gravitational pull to modify its path, eventually achieving its ultimate orbit around the Sun. As the probe advances on its mission, its instruments will gather important data on solar energy transfers, enhancing our knowledge of the Sun’s influence on Earth. Studies such as this are vital, given that our planet's dependence on the Sun necessitates an understanding of the dynamics within our solar system. The Parker Solar Probe’s Exploration of Venus In addition to its tasks close to the Sun, Parker’s technology also aided in the exploration of Venus. Utilizing its camera, the Parker Solar Probe's Wide-Field Imager (WISPR) obtained distinctive images of Venus while flying past. Although the dense cloud cover usually hides the planet's surface, WISPR's near-infrared features enabled it to observe the luminous surface of Venus, uncovering the planet's intense heat. Noam Izenberg, a space scientist at the Johns Hopkins Applied Physics Laboratory, emphasized the importance of these findings, describing them as a crucial advance in comprehending Venus' extreme conditions. Get Latest News Live on Times Now along with Breaking News and Top Headlines from World and around the world.

PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company’s Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. “This strategic transaction highlights Vincerx’s commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer. “Oqory’s anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings.” About OQY-3258 (also known as ESG401) OQY-3258 is Oqory’s anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory’s product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx’s control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx’s capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties’ ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx’s reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.com

No. 24 Arizona is coming off consecutive defeats for the first time in the Tommy Lloyd era when it faces undefeated Davidson on Wednesday to begin the Battle 4 Atlantis in Paradise Island, Bahamas. Arizona (2-2) lost at Wisconsin 103-88 on Nov. 15 and followed that with a home loss against Duke 69-55 on Friday. The Wildcats have dropped 15 spots in the Associated Press Top 25 poll in two weeks. Arizona's record is .500 this early in a season for the first time since it was 3-3 to start the 2017-18 schedule. "I've got work to do, so let's get to work," said Lloyd, in his fourth year as Arizona's head coach. "Let's see where we're at in a month, and if we're still struggling, you know what I'll do? I still got work to do, but I'm gonna get to it." Arizona shot 39.6 percent from the field against Duke, and just 26.1 percent (6 of 23) from 3-point range. The Wildcats were outrebounded by 43-30 and their 15 turnovers led to 19 points. Jaden Bradley led Arizona with 18 points and KJ Lewis added 12. Preseason All-American Caleb Love had eight points on 3-of-13 shooting from the field, including 1-of-9 from 3-point range. Arizona made only one field goal in the last 5:39 as Duke pulled away after its lead was trimmed to six points. "We didn't play great," Lloyd said. "Now we need to take a step back and figure out why. Are there some schematic problems? Are there some problems with how our personnel is kind of put together? "We got to figure out what our certainties are, and the things we have to have, and then over the course of the next couple of days, if there's adjustments we need to make, we need to figure out what those are." Davidson is 4-0 after a 15-17 record last season, in which it lost its last six games to put an end to postseason hopes. A 93-66 win over visiting VMI on Friday followed a 91-85 win at Bowling Green and 76-70 victory over visiting East Tennessee State. The two wins by 10 points or fewer are important because Davidson was 6-12 in such games last season. It was 4-11 in games decided by five points or fewer. "The goal (is) to get better," Davidson head coach Matt McKillop said after the season opener. "We talk about fighting to win every possession. I think we had to figure out what that really felt like with the lights on." Davidson made 13 shots from 3-point range in the win over VMI. Reed Bailey had 23 points, eight rebounds and six assists. Bobby Durkin added 19 points, including 17 of them and a career-best five 3-pointers in the first half. Bailey leads Davidson in scoring (19 points per game) and rebounding (7.8). Durkin is shooting 57.9 percent (22 of 38) from the field and 54.2 percent (13 of 24) from 3-point range. By contrast, Arizona's Love is shooting 32 percent (16 of 50) from the field and 21.4 percent (6 of 28) from beyond the arc. Bradley leads Arizona with 15.5 points per game. He is shooting 50 percent (24 of 48) from the field and is 35.7 percent (5 of 14) from 3-point range. --Field Level Media

Mobile phones turned 40 in 2024, but there’s no need for a foldables or AR glasses fueled midlife crisis before they're 50SAN JOSE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that Nimrod Ben-Natan , President and CEO of Harmonic, and Walter Jankovic , Harmonic's Chief Financial Officer, will participate in a fireside chat at the Raymond James 2024 TMT and Consumer Conference in New York City , on Monday, December 9, 2024 at 8:20 a.m. PT / 11:20 a.m. ET and host investor meetings throughout the day. Mr. Jankovic will also host investor meetings at the Barclays 2024 Global Technology Conference in San Francisco , on Thursday, December 12, 2024 . A live audio webcast of the fireside chat will be available on Harmonic's website at investor.harmonicinc.com . An archived webcast will remain posted on the Company's investor relations website for 30 days. Further information about Harmonic and the company's solutions is available at https://www.harmonicinc.com/ . About Harmonic Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry's first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet service to consumers' homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet cable services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at https://www.harmonicinc.com/ . Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners . View original content to download multimedia: https://www.prnewswire.com/news-releases/harmonic-to-participate-in-upcoming-december-2024-investor-conferences-302316838.html SOURCE Harmonic Inc.

Kylie Kelce says she’s ‘not going to stop cursing’ in front of kids in trailer for new podcastUpstart Holdings CEO Dave Girouard sells $305,248 in stock

Jurors end 1st day of deliberations without a verdict in the YSL gang and racketeering trial

No. 16 Cincinnati tests efficient offense vs. Alabama State

No. 16 Cincinnati tests efficient offense vs. Alabama State

'Ignore the Scrooges, get Christmas started early to distract us from World War Three'As feathers flew, Tim Walz accepted the symbolic presentation of a turkey Tuesday as he eases back into his duties as Minnesota’s governor following the Harris-Walz ticket’s defeat in the presidential election. Unlike the Minnesota-grown turkeys that President Joe Biden pardoned at the White House on Monday, Walz didn’t pardon this turkey, he said, “because in Minnesota we know turkeys are delicious.” The 41.8-pounder named Tom was raised by Paisley VonBerge, a Future Farmers of America leader from Hutchinson, and it will star in her family’s Thanksgiving dinner. It flapped its wings and shed feathers as she hoisted it onto a display table but quickly calmed down, oblivious to its fate. “After today, this bird will go back to my farm to be enjoyed the way that turkeys are intended,” Paisley said. “That is very Minnesotan,” Walz added to loud laughter. “We don’t hide the fact we love our turkeys.” Minnesota produces more turkeys annually than any other state. Its farmers raised 38.5 million birds in 2023, according to U.S. Department of Agriculture statistics, followed by North Carolina at 29 million. North Carolina edged Minnesota last year in total poundage, producing just over 1.07 billion pounds, compared with just over 1.05 billion pounds for Minnesota. The ceremony in the governor’s reception room was the first time Walz had met with reporters at the state Capitol since last summer, before Vice President Kamala Harris picked him as her running mate. While Walz has held private meetings in recent weeks with staff, legislative leaders and other public officials, interviewed potential judicial appointees, and fielded some press questions, he’s still ramping back up with public events. He said Tuesday that he had no regrets about agreeing to run — and is proud he did. The Walz-Harris ticket got over 74 million votes to nearly 77 million for President-elect Donald Trump. While Walz said that shows that many Americans liked the message he and Harris put out, he acknowledged it was “not quite enough.” “I was just glad to be out there, and to be honest, glad to tell Minnesota’s story — that we get things done together and we’re pretty hopeful people,” he told reporters. Walz is already preparing for the upcoming legislative session, when he and his fellow Democrats will have to share power with Republicans — a contrast with the last two years when they enjoyed the “trifecta” of controlling the governor’s office and both the state House and Senate. While Democrats kept their one-vote majority in the Senate, recounts that wrapped up Monday confirmed that the House will be tied 67-67 when lawmakers convene Jan. 14, barring successful court challenges. Related Articles Politics | In push to break tie with House DFL, Republicans say they’ll challenge election in southwest metro Politics | Federal lawsuit seeks to overturn MN abortion protections Politics | Health providers dropping Medicare Advantage could affect coverage for 60,000 Minnesotans Politics | Ramsey County judge halts cannabis license lottery that is precursor to Minnesota marijuana retail launch Politics | Divided MN Legislature will have to pass budget with looming shortfalls this session House Republicans announced Tuesday that they plan to sue to contest one race, where incumbent Democratic Rep. Brad Tabke, of Shakopee, won his recount by 14 votes, but where Scott County elections officials are still trying to determine what happened to 21 absentee ballots that might be missing. Even assuming the tie holds up, it’s going to force compromises if lawmakers are going to pass a balanced budget before the session ends in May. But Walz said they proved power sharing could work in 2019, when Republicans controlled the Senate and Minnesota was one of the few states with a divided Legislature. “We’re going to have some opportunities to continue to move in the positive direction we’ve gone,” Walz said.Arteta wanted his team to prove their European credentials following some underwhelming displays away from home, and the Gunners manager got exactly what he asked for. Goals from Gabriel Martinelli, Kai Havertz, Gabriel Magalhaes, Bukayo Saka and Leandro Trossard got their continental campaign back on track in style following the 1-0 defeat at Inter Milan last time out. A memorable victory also ended Sporting’s unbeaten start to the season, a streak of 17 wins and one draw, the vast majority of which prompted Manchester United to prise away head coach Ruben Amorim. The Gunners had failed to win or score in their two away games in the competition so far this season, but they made a blistering start in the Portuguese capital and took the lead after only seven minutes. Declan Rice fed overlapping full-back Jurrien Timber, who curled a low cross in behind the home defence for Martinelli to finish at the far post. Arsenal doubled their lead in the 20th minute thanks to a glorious ball over the top from Thomas Partey. Saka escaped the clutches of his marker Maximiliano Araujo to beat the offside trap and poke the ball past advancing goalkeeper Franco Israel for Havertz to tap home. It was a scintillating first-half display which completely overshadowed the presence of Viktor Gyokeres in Sporting’s attack. The prolific Sweden striker, formerly of Coventry, has been turning the heads of Europe’s top clubs with his 24 goals in 17 games this season – including a hat-trick against Manchester City earlier this month. But the only time he got a sniff of a run at goal after an optimistic long ball, he was marshalled out of harm’s way by Gabriel. David Raya was forced into one save, tipping a fierce Geovany Quenda drive over the crossbar. But Arsenal added a third on the stroke of half-time, Gabriel charging in to head Rice’s corner into the back of the net. To rub salt in the wound, the Brazilian defender mimicked Gyokeres’ hands-over-his-face goal celebration. That may have wound Sporting up as they came out after the interval meaning business, and they pulled one back after Raya tipped Hidemasa Morita’s shot behind, with Goncalo Inacio netting at the near post from the corner. Former Tottenham winger Marcus Edwards fired over, as did Gyokeres, with Arsenal temporarily on the back foot. But when Martin Odegaard’s darting run into the area was halted by Ousmane Diomande’s foul, Saka tucked away the penalty. Substitute Trossard added the fifth with eight minutes remaining, heading in the rebound after Mikel Merino’s shot was saved, and Gyokeres’ miserable night was summed up when his late shot crashed back off the post.

DEIR AL-BALAH, Gaza Strip (AP) — Israeli troops stormed one of the last hospitals operating in northern Gaza on Friday, forcing many staff and patients outside to strip in winter weather , the territory’s health ministry said. The army denied claims it had entered or set fire to the complex and accused Hamas of using the facility for cover. Kamal Adwan Hospital has been hit multiple times over the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods, according to staff. The ministry said a strike on the hospital a day earlier killed five medical staff. Israel's military said it was conducting operations against Hamas infrastructure and militants in the area and had ordered people out of the hospital, but said it had not entered the complex as of Friday night. It repeated claims that Hamas militants operate inside Kamal Adwan but provided no evidence. Hospital officials have denied that. The Health Ministry said troops forced medical personnel and patients to assemble in the yard and remove their clothes. Some were led to an unknown location, while some patients were sent to the nearby Indonesian Hospital, which was knocked out of operation after an Israel raid this week. Israeli troops during raids frequently carry out mass detentions, stripping men to their underwear for questioning in what the military says is a security measure as they search for Hamas fighters. The Associated Press doesn’t have access to Kamal Adwan, but armed plainclothes members of the Hamas-led police forces have been seen in other hospitals, maintaining security but also controlling access to parts of the facilities. The Health Ministry said Israeli troops also set fires in several parts of Kamal Adwan, including the lab and surgery department. It said 25 patients and 60 health workers remained in the hospital. The account could not be independently confirmed, and attempts to reach hospital staff were unsuccessful. “Fire is ablaze everywhere in the hospital,” an unidentified staff member said in an audio message posted on social media accounts of hospital director Hossam Abu Safiya. The staffer said some evacuated patients had been unhooked from oxygen. “There are currently patients who could die at any moment,” she said. Lt. Col. Nadav Shoshani, an Israeli military spokesman, denied the accusations. “While IDF troops were not in the hospital, a small fire broke out in an empty building inside the hospital that is under control,” he said Friday night. He said a preliminary investigation found “no connection” between military activity and the fire. The Israeli military heavily restricts the movements of Palestinians in Gaza and has barred foreign journalists from entering the territory throughout the war, making it difficult to verify information. “These actions put the lives of all of these people in even more danger than what they faced before,” U.N. spokesperson Stephanie Tremblay told journalists, and noted colleagues' reports of “significant damage” to the hospital. It should be protected as international law requires, she added. Since October, Israel’s offensive has virtually sealed off the northern Gaza areas of Jabaliya, Beit Hanoun and Beit Lahiya and leveled large parts of them. Tens of thousands of Palestinians were forced out but thousands are believed to remain in the area, where Kamal Adwan and two other hospitals are located. Troops raided Kamal Adwan in October, and on Tuesday troops stormed and evacuated the Indonesian Hospital. The area has been cut off from food and other aid for months , raising fears of famine . The United Nations says Israeli troops allowed just four humanitarian deliveries to the area from Dec. 1 to Dec. 23. The Israeli rights group Physicians for Human Rights-Israel this week petitioned Israel’s High Court of Justice, seeking a halt to military attacks on Kamal Adwan. It warned that forcibly evacuating the hospital would “abandon thousands of residents in northern Gaza.” Before the latest deaths Thursday, the group documented five other staffers killed by Israeli fire since October. Israel launched its campaign in Gaza vowing to destroy Hamas after the group’s Oct. 7, 2023, attack on southern Israel in which militants killed around 1,200 people and abducted some 250 others. Around 100 Israelis remain captive in Gaza, around a third believed to be dead. Israel’s nearly 15-month-old campaign of bombardment and offensives has devastated the territory’s health sector. A year ago, it carried out raids on hospitals in northern Gaza, including Kamal Adwan, Indonesian and al-Awda Hospital, saying they served as bases for Hamas, though it presented little evidence. Israel’s campaign has killed more than 45,400 Palestinians, more than half women and children, and wounded more than 108,000 others, according to the Health Ministry. Its count does not distinguish between civilians and combatants. More than 90% of Gaza’s 2.3 million Palestinians have been driven from their homes, most now sheltering in sprawling tent camps in south and central Gaza. Children and adults, many barefoot, huddled Friday on the cold sand in tents whose plastic and cloth sheets whipped in the wind. Overnight temperatures can dip into the 40s Fahrenheit (below 10 Celsius), and sea spray from the Mediterranean can dampen tents just steps away. "I swear to God, their mother and I cover ourselves with one blanket and we cover (their five children) with three blankets that we got from neighbors. Sea waters drowned everything that was ours,” said Muhammad al-Sous, displaced from Beit Lahiya in the north. The children collect plastic bottles to make fires, and pile under the blankets when their only set of clothes is washed and dried in the wind. At least three babies in Gaza have died from exposure to cold in recent days , doctors there have said, and the Health Ministry said an adult — a nurse who worked at the European Hospital — also died this week. Khaled and Keath reported from Cairo. Associated Press writer Edith M. Lederer at the United Narions contributed to this report.GTA 6 Moon Theory Debunked, Fans Devastated - IGN Daily Fix

Arsenal star Gabriel Magalhaes appears to MOCK Viktor Gyokeres with trademark celebration after scoring header against Sporting LisbonCanada's financial intelligence agency aiming to provide crucial info in real time OTTAWA — Canada's financial intelligence agency says it is modernizing with the aim of providing valuable information to police and security officials in real time — or as close to that goal as it can get. Jim Bronskill, The Canadian Press Nov 26, 2024 10:58 AM Nov 26, 2024 11:05 AM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message OTTAWA — Canada's financial intelligence agency says it is modernizing with the aim of providing valuable information to police and security officials in real time — or as close to that goal as it can get. In its newly released annual report, the Financial Transactions and Reports Analysis Centre of Canada says it is working with businesses and federal partners to move more quickly in the fight against money laundering and terrorist financing. The agency, known as Fintrac, identifies money linked to illicit activities by electronically sifting millions of pieces of information each year from banks, insurance companies, money services businesses, real-estate brokers, casinos and others. In turn, it discloses intelligence to police and security agencies about the suspected cases. In 2023-24, Fintrac produced more than 4,600 financial intelligence disclosure packages for recipients including the RCMP, municipal and provincial police, the Canada Border Services Agency and the Canada Revenue Agency. In a message in the report, Fintrac director Sarah Paquet says the agency aims to harness modern skills, tools and technologies to analyze data and produce intelligence in real time. Paquet said such swiftness could be a game-changer, for example, in the agency's efforts to track financial transactions related to human trafficking for sexual exploitation. "It will allow us to proactively identify and assist law enforcement in disrupting networks much quicker," she said. "This will mean rescuing victims sooner, saving them from prolonged abuse. It will mean supporting survivors sooner, getting them the assistance they need in a more timely fashion. And it will help law enforcement target, arrest and charge the traffickers sooner, preventing the abuse of new victims." Fintrac's digital strategy includes advancing automation, analytics and the use of artificial intelligence, Paquet said. In a bid to "stay ahead of the bad actors," Fintrac has created a digital acceleration and modernization team "to experiment with, and exploit, the latest technologies." Transnational organized crime groups and professional money launderers are the most prominent threats to Canada when it comes to illicit cash transactions, the report said. "At the same time, while the threat of terrorist financing is not as pronounced in Canada as it is in other regions of the world, there are networks operating in our country that are suspected of raising, collecting and transmitting funds abroad to various terrorist groups." This report by The Canadian Press was first published Nov. 26, 2024. Jim Bronskill, The Canadian Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message More National Business 'Let's do this': Crowsnest Pass mayor wants proposed coal mine sooner than later Nov 26, 2024 11:34 AM Barrick Gold says four employees charged and detained pending trial in Mali Nov 26, 2024 11:22 AM ‘Who profits on hunger?’ Inuit send pleading emails to minister about food costs Nov 26, 2024 11:10 AM Featured Flyer

Article content WASHINGTON — Donald Trump threatened the United States’s closest neighbours with big tariffs this week, in a move that has reminded many of the unpredictable tactics the president-elect deployed during his first tenure in the White House. Recommended Videos Trump said Monday he would use an executive order to impose 25% tariffs on all goods coming from Canada and Mexico until the two countries stop drugs and migrants from illegally crossing the U.S. border. The announcement, made on Truth Social, brought swift responses from officials and industry in both countries who are bracing for chaos during Trump’s second tenure. He has long used the threat of import taxes to pressure other countries to do his bidding, saying this summer that “the most beautiful word in the dictionary is ‘tariff.'” It’s unlikely the move would violate the Canada-U.S.-Mexico Agreement, which was negotiated during the first Trump administration. Laura Dawson, an expert on Canada-U. S. relations and the executive director of the Future Borders Coalition, said the president can impose tariffs under his national security powers. This type of duty has a time limit and can only be made permanent through Congressional approval, but for Trump, national security powers are like a “get out of jail free card,” Dawson said. “This is exactly what happened in the last Trump administration,” Dawson said. “Everyone said, ‘Well, that is ridiculous. Canada is the U.S.’s best security partner. What do you mean our steel and aluminum imports are somehow a source of insecurity?”‘ But within the global trade system, she said, no country challenges another’s right to define their own national security imperatives. Trump’s first administration demonstrated how vulnerable Canada is to America’s whims when the former president scrapped the North American Free Trade Agreement. The U.S. is Canada’s closest neighbour and largest trading partner. More than 77% of Canadian exports go to the U.S. Negotiation of CUSMA, commonly dubbed “the new NAFTA,” was a key test for Ottawa following Trump’s first victory. The trilateral agreement is up for review in 2026 and experts suspect this week’s tariff announcement is a negotiating tactic. Scott Bessent, Trump’s pick for treasury secretary, said in a recent op-ed that tariffs are “a useful tool for achieving the president’s foreign policy objectives. “Whether it is getting allies to spend more on their own defence, opening foreign markets to U.S. exports, securing co-operation on ending illegal immigration and interdicting fentanyl trafficking, or deterring military aggression, tariffs can play a central role.” During the initial CUSMA negotiations in 2018, Trump floated the idea of a 25% tariff on the Canadian auto sector — something that would have been crippling for the industry on both sides of the border. It was never implemented. At the time, he did use his national security powers to impose a 25% tariff on steel and a 10% tariff on aluminum imports, casting fear of an all-out trade war that would threaten the global economy. The day after announcing those levies, Trump posted on social media “trade wars are good, and easy to win.” RECOMMENDED VIDEO Former U.S. trade representative Robert Lighthizer recounted in his book that the duties sent an “unmistakable signal that business as usual was over. “The Trump administration was willing to ruffle diplomatic feathers to advance its trade agenda.” It led to a legendary clash between Prime Minister Justin Trudeau and Trump at the G7 in Quebec. Trudeau said Canada would impose retaliatory measures, saying the argument that tariffs on steel and aluminum were a matter of national security was “kind of insulting.” Trump took to social media, where, in a flurry of posts he called Trudeau “very dishonest and weak.” Canada and other countries brought their own duties against the U.S. in response. They targeted products for political, rather than economic, reasons. Canada hit yogurt with a 10% duty. Most of the product impacted came from one plant in Wisconsin, the home state of then-Republican House Speaker Paul Ryan. The European Union, Mexico and Canada all targeted U.S. whiskey products with tariffs, in a clear signal to then Republican Senate Majority Leader Mitch McConnell and his home state of Kentucky’s bourbon industry. RECOMMENDED VIDEO Ultimately, Canada and Mexico were able to negotiate exemptions. Carlo Dade, the director of trade and trade infrastructure at the Canada West Foundation, said Trump is returning to the White House with more experience and a plan. But he suspects Americans will not like the blow to their bank accounts. Trump’s new across-the-board tariff strategy would not only disrupt global supply chains, it would also cause a major shakeup to the American economy. It’s unclear if Trump will go through with them, or for how long, after campaigning on making life more affordable and increasing the energy market. “I think it will be short term,” Dade said. “The U.S. can only inflict damage on itself for so long.” — With files from The Associated Press.YOURSAY | Govt should do more to control soaring food prices

Glance into windows as you walk down any street at the moment and you’ll be greeted by the sight of fairy lights twinkling from within fir branches. Ahh Christmas, that magical time when it is suddenly completely normal to invite a massive tree inside, to live in your front room. But wait! What madness is this? It’s still November! Despite tradition dictating that in polite British society we wait until December at the very least, a YouGov survey has revealed that 11% of Brits had already put their trees and decorations up by November 25 this year. So why have so many people pulled the trigger early? Maybe it’s the Tinsel Index – a sister theory to the Hemline Index, which suggests that women’s skirt lengths directly correlate with economic conditions, so minis during booms, maxis during recessions. The Tinsel Index means that the more miserable things are generally in the world, the earlier people try to cheer themselves up with festive ­accoutrements. You don’t have to think long to work out what we need to be distracted from this year – take your pick from the freezing weather, cost-of-living crisis, wars including the threat of World War Three, floods ... could go on and on, but let’s stop there, because there aren’t enough baubles on the planet. And so, people have embraced the season to be jolly a little ­expeditiously this year – if it makes them feel a little better, what’s the harm, right? But of course it’s not that simple. Alongside those minding their own business and putting what they want in their own houses are others, absolutely outraged by what complete strangers are doing, and by what date. It’s almost as if that anger is perhaps misplaced, and not really about Christmas trees, but let’s not pull at that thread, eh? And so they post on social media about it being a travesty, mutter disapprovingly whenever they see premature forestation, shake their heads and tut at news of people – gasp! – already eating mince pies. The difference any of this makes to them, to their lives, to when they put their own trees up? Nil, zero, nada, nothing. And yet they seem to be taking it as a personal insult. In theory, I’m actually on their side. Every year, around this time, our heartwarming family tradition is a huge argument between my husband and I about when to put up our tree He’s relentlessly merry by nature, and would like our home to be fully Christmafied from July to February. I would ideally put the tree up a week before the 25th, and evict it on Boxing Day, when it is no longer relevant and I’m embarrassed for it. It is one of those arguments that’s been had so many times we both know exactly what the other will say next, and that we’ll end up getting a tree on December 10 so neither of us is happy. This year though, anything goes, and let’s try not to be ­judgmental about it. Everyone should just do whatever they feel will bring a little light into their lives – let the season of goodwill stretch out as far as the eye can see, in all directions. Who knows, maybe I’ll even concede defeat personally too. Husband, December 9 it is!

Trump asks Supreme Court to delay TikTok ban so he can weigh in after he takes officeBlinken faces GOP critics in Congress who say Afghanistan withdrawal 'lit the world on fire'